Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426
Powles, T. Plimack, E. R. Stus, V. Waddell, Thomas Gafanov, R. Pouliot, F. Nosov, D. Melichar, B. Soulieres, D. Borchiellini, D.
Powles, T.
Plimack, E. R.
Stus, V.
Waddell, Thomas
Gafanov, R.
Pouliot, F.
Nosov, D.
Melichar, B.
Soulieres, D.
Borchiellini, D.
Citations
Altmetric:
Abstract
Authors
Powles, T.
Plimack, E. R.
Stus, V.
Waddell, Thomas
Gafanov, R.
Pouliot, F.
Nosov, D.
Melichar, B.
Soulieres, D.
Borchiellini, D.
Vynnychenko, I.
McDermott, R. S.
Azevedo, S. J.
Tamada, S.
Kryzhanivska, A.
Li, C.
Burgents, J. E.
Molife, L. R.
Rini, B. I.
Bedke, J.
Plimack, E. R.
Stus, V.
Waddell, Thomas
Gafanov, R.
Pouliot, F.
Nosov, D.
Melichar, B.
Soulieres, D.
Borchiellini, D.
Vynnychenko, I.
McDermott, R. S.
Azevedo, S. J.
Tamada, S.
Kryzhanivska, A.
Li, C.
Burgents, J. E.
Molife, L. R.
Rini, B. I.
Bedke, J.
Affiliation
Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London, London
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Powles T, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301334.